Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb:54:139-148.
doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5.

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

J M Michot  1 , C Bigenwald  2 , S Champiat  3 , M Collins  4 , F Carbonnel  4 , S Postel-Vinay  3 , A Berdelou  2 , A Varga  3 , R Bahleda  3 , A Hollebecque  3 , C Massard  3 , A Fuerea  5 , V Ribrag  5 , A Gazzah  3 , J P Armand  3 , N Amellal  3 , E Angevin  3 , N Noel  6 , C Boutros  7 , C Mateus  7 , C Robert  7 , J C Soria  3 , A Marabelle  3 , O Lambotte  6
Affiliations
Review

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

J M Michot et al. Eur J Cancer. 2016 Feb.

Abstract

Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents are used to target immune cells rather than cancer cells. The first generation of new immunotherapies corresponds to antagonistic antibodies that block specific immune checkpoint molecules cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein (PD-1) and its ligand PD-L1. Targeting these checkpoints in patients living with cancer had led to long-lasting tumour responses. By unbalancing the immune system, these new immunotherapies also generate dysimmune toxicities, called immune-related adverse events (IRAEs) that mainly involve the gut, skin, endocrine glands, liver, and lung but can potentially affect any tissue. In view of their undisputed clinical efficacy, anti-CTLA-4 and anti-PD-1 antibodies are entering in the routine oncological practice, and the number of patients exposed to these drugs will increase dramatically in the near future. Although steroids can be used to treat these IRAEs, the associated immunosuppression may compromise the antitumour response. Oncologists must be ready to detect and manage these new types of adverse events. This review focuses on the mechanisms of IRAE generation, putative relationship between dysimmune toxicity and antitumour efficacy, as a basis for management guidelines.

Keywords: Anti-PD-1 antibody; Cytotoxic T-lymphocyte-associated antigen 4; Immune checkpoint blockade; Immune-related adverse events; Tumour neoantigen.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms